AP732A - Substances extracted from dictyotales, preparation method therefor, and compositions containing same. - Google Patents
Substances extracted from dictyotales, preparation method therefor, and compositions containing same. Download PDFInfo
- Publication number
- AP732A AP732A APAP/P/1997/001085A AP9701085A AP732A AP 732 A AP732 A AP 732A AP 9701085 A AP9701085 A AP 9701085A AP 732 A AP732 A AP 732A
- Authority
- AP
- ARIPO
- Prior art keywords
- active substances
- substances according
- biologically
- biologically active
- dictyotales
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 241000199916 Dictyotales Species 0.000 title claims abstract description 44
- 239000000126 substance Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title description 3
- 239000013543 active substance Substances 0.000 claims abstract description 83
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 33
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 28
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 28
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 28
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 26
- 210000001519 tissue Anatomy 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000377 silicon dioxide Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 16
- 230000014759 maintenance of location Effects 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 239000001117 sulphuric acid Substances 0.000 claims description 12
- 102000016611 Proteoglycans Human genes 0.000 claims description 11
- 108010067787 Proteoglycans Proteins 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- 238000002953 preparative HPLC Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000004809 thin layer chromatography Methods 0.000 claims description 7
- -1 phophomolybdate Substances 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 125000003367 polycyclic group Chemical group 0.000 claims description 3
- 238000002211 ultraviolet spectrum Methods 0.000 claims description 3
- 239000003849 aromatic solvent Substances 0.000 claims description 2
- 150000001924 cycloalkanes Chemical class 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000011368 organic material Substances 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims 4
- 150000002009 diols Chemical class 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 description 59
- 210000002950 fibroblast Anatomy 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 102000000589 Interleukin-1 Human genes 0.000 description 17
- 108010002352 Interleukin-1 Proteins 0.000 description 17
- 210000001612 chondrocyte Anatomy 0.000 description 16
- 239000002609 medium Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 10
- 229920002674 hyaluronan Polymers 0.000 description 10
- 229960003160 hyaluronic acid Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 210000000963 osteoblast Anatomy 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 239000005418 vegetable material Substances 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 235000010980 cellulose Nutrition 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000011149 sulphuric acid Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000004264 monolayer culture Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 229940088623 biologically active substance Drugs 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011158 quantitative evaluation Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- 241000030950 Padina Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000012822 chemical development Methods 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 241000199924 Dictyota Species 0.000 description 1
- 241000199915 Dictyotaceae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000017177 Fibromodulin Human genes 0.000 description 1
- 108010013996 Fibromodulin Proteins 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 241001112262 Gymnospora Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000030972 Padina tenuis Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102000003711 Syndecan-2 Human genes 0.000 description 1
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 241001627080 Zonaria <gastropod> Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- FVMOEFABYNPCDS-UHFFFAOYSA-L calcium;1-(4-carboxy-2,6-dioxocyclohexylidene)propan-1-olate Chemical compound [Ca+2].CCC([O-])=C1C(=O)CC(C(O)=O)CC1=O.CCC([O-])=C1C(=O)CC(C(O)=O)CC1=O FVMOEFABYNPCDS-UHFFFAOYSA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004200 deflagration Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Biological substances and particularly biologically active substances of marine origin are disclosed. The novel biologically active substances are extracts of plants of the dictyotales family and have characteristic analytical properties. A method for preparing said novel substances and pharmaceutical, cosmetic and/or food compositions containing such substances are also disclosed. Said biologically active substances are useful for preparing pharmaceutical, cosmetic and/or food compositions for altering the synthesis of glycosylated elements in the extracellular matrix of human and animal tissues.
Description
SUBSTANCES EXTRACTED FROM DICTYOTALES, A PROCESS FOR
OBTAINING THEM AND COMPOSITIONS COMPRISING THEM
The present invention relates to the field of biology, and more precisely to biologically active substances of marine origin.
The present invention relates to new biologically active substances extracted from plants of the family of the Dictyotales, a process for obtaining them and compositions comprising them.
io
The compositions of the present invention are intended for modification of the synthesis of glycosylated elements of the extracellular matrix (ECM) of animal and human tissues.
The term plants of the family of the Dictyotales is to be understood as meaning, more particularly, those which are capable of fixing, condensing, precipitating or effecting the synthesis, on their thallus, of calcium carbonate in the crystalline form called aragonite.
The term plants may relate to the dried or fresh, ground or untreated plant.
The plants of which the biologically active substances of the invention are extracted are the Pheophyceae, class of the Fucophyceae, order of the Dictyotales, family of the Dictyotaceae. Only some genera belong to the family of the Dictyotales, and these are Padina, Zonaria or Dictyota. The genus Padina comprises the most frequent species. By way of example, it is possible to find on the shore of the Mediterranean Sea the species pavonica, boyana (P. tenuis) and boergesenii, on the shores of the Pacific (not including the species already mentioned): arborescens, australis, boryana, caulens, commersonii, concrescens, crasse, durvillei, elegans, fernandeziana, fraseri and gymnospora, and furthermore on the shores of the Atlantic Ocean: glabra, haitensis, distromatica and dubia. There are also species typical of the Indian Ocean. One of the characteristics of these plants is that of fixing, on their thallus, a layer of calcium carbonate of the aragonite or orthorhombic type on the surface of the fronds. This characteristic is detected by XA»- . υ υ 7 S ί
Ί ray diffraction analysis of the powder obtained with these plants. X-ray diffraction shows that the powder of these plants has significant intensity peaks at the angles 2 Θ: -3.393°, -3.268°, -2.699°, -2.682°, -2.371°, -2.336° (doublet), -1.976¾ and -1.877° (doublet). These diffraction angles are characteristic of aragonite.
The present invention relates to new biologically active substances which modify the synthesis of glycosylated elements of the extracellular matrix of animal and human tissues and which are extracted from plants of the family of the Dictyotales.
These new biologically active substances are characterized in particular by a polycyclic structure carrying a side chain having 4 to 10 carbon atoms in a straight io or branched line and containing one or two double bonds.
The new substances are also characterized by more precise analytical data.
The present invention also relates to a process for obtaining the biologically active substances extracted from plants of the family of the Dictyotales.
In a first stage, the plant of the family of the Dictyotales is subjected, after harvesting, to drying, if possible in the absence of light, to keep its pharmacological » properties intact
Slow drying with significant insolation leads to substances which are not very active and are unstable when being obtained. Drying by more appropriate methods, with the main condition that active substances are obtained, are therefore preferably used.
For this reason, drying of the ground or untreated plants is carried out by ventilation without heating, and a vegetable material of dark maroon colour, on which the white streaks of calcium carbonate contrast vividly, is thus obtained.
Another method, although less economical, is also satisfactory: It comprises draining the plants to a high degree and then drying them in the absence of air. Lyophilization of the ground or non-ground plant gives an anhydrous product in an advantageous manner.
These last two techniques give a material of dark green-brown colour which is very fragile and easily reduced to a powder, which facilitates extraction with a solvent to give the biologically active substances.
AP/P/ S 7 / 0 1 0 8 5
AP. 0 0 7 3 2
The advantage of a plant which has been dried to a high degree is that a vegetable material which keeps well (in the absence of moisture) is obtained, from which it will be possible to extract the stabilized or non-stabilized active substance or substances without being impeded by the presence of a polar solvent. Furthermore, completely dried plants are more easily reduced to a powder.
The process for the preparation of the biologically active substances is characterized in that the plant of the family of the Dictyotales is subjected to drying and/or to lyophilization, to grinding, followed by one or more extractions of the io vegetable material by an organic solvent chosen from the group consisting of lower alkanols (ethanol...), aliphatic ketones (acetone...), alkanes (pentane, hexane, heptane...), cycloalkanes (cyclohexane...), halogenated solvents (chloroform, methylene chloride...), aromatic solvents, esters (ethyl acetate...), ethers and the like, to give an organic extract of the plant, the organic extract is dried by evaporation of the solvent, the dried organic extract is purified by one or more purification stages carried out successively by liquid/liquid contact, by low pressure or high pressure column chromatography or by high performance liquid chromatography, to give the active substances of plants of the family of the Dictyotales.
The organic solvents can be used by themselves or in combination. Generally, it is possible to use water-miscibie organic solvents, as well as all solvents capable of extraction of the active substances from the fronds of the plant.
The solvents will preferably be chosen from among the volatile solvents, since it is desirable to obtain the biologically active substances freed from the solvent. In fact, the volatile solvents which dissolve the biologically active substances can be evaporated from a support, such as cellulose or its derivatives, colloidal silica, high molecular weight alkanes, such as paraffins, amphiphilic solvents, such as polyethylene glycol (PEG) or propylene glycol, or also inert products, such as glycerol and the like.
s 8 0 1 0 ! L 6 /d/dV
The organic solvents will preferably be acetone or ethanol.
AP. Ο Ο 7 3 2
The ratio used is preferably 1 gram of dried vegetable material per 5 ml of solvent, and the contact times between the vegetable material and the organic solvent are preferably 4 to 5 days.
However, during the maceration, very different ratios of dried material with respect to the solvent have been used with good results. The volumes used for the same amount of dried material vary from 1 to 50. Furthermore, the contact times between the organic solvent and the vegetable material vary from 12 hours to 5 days.
io Moreover, although more difficult to use, aqueous extraction in an ammoniacal medium gives satisfactory results.
To carry out the extraction of the biologically active substances, it is not necessary to macerate the vegetable material in the solvent chosen, and it is possible to pass the solvent continuously over the powder (percolation). It is sufficient to regulate the flow rate and to concentrate the extract to obtain a solution of chosen activity.
In the present case, the plant of the family of the Dictyotales, once dried and/or «
lyophilized and ground, is subjected to one or more extractions by bringing the plant into contact with acetone for 4 to 5 days in proportions of 1 gram of material per 5 ml of acetone.
The acetone extract obtained is dried by evaporation of the solvent and then purified by the purification stages defined below.
The first purification stage is carried out by liquid/liquid contact. The dried acetone residue or extract is taken up in a methanol/water mixture in contact with hexane. In a second stage, the aqueous-methanolic phase is brought into contact, after concentration and dilution in water, with ether.
In this manner, the final ethereal phase is biologically active.
The second purification stage is characterized by low pressure column chromatography. The support used is a gel of the Sephadex LH 20® type.
The elution is carried out by a chloroform/methanol gradient. The biologically active fraction is eluted in chloroform/methanol in proportion of 97/3 volume by Volume.
AP/F/ 9 7 / 0 1 0 8 5
AP.00732
During rinsing of the column with a chloroform/methanol 70/30 mixture, a second residual active fraction is eluted.
The following stages of purification take place by semi-preparative high performance liquid chromatography (HPLC). The dimensions of the column are 250 mm (for the length) and 10 mm (for the diameter). The supports used are: Ci8-grafted silica and a diol-grafted silica. The flow rate is 8 ml/min.
On the diol-grafted silica support, with an eluent of hexane/isopropanol 92/8, the active fractions are eluted between 20 and 25 min and 35 and 40 min.
io On the C18-grafted silica support, with an eluent of acetonitrile/water 85/15, the active fraction is eluted between 15 and 17 min, and with an eluent of acetonitrile/water/acetic acid 85/15/0.05, the active fractions are eluted between 17 and 20 min and 30 and 40 min.
At the end of these purification stages, a biologically active substance of yellowgreen colour is obtained.
Various analytical methods (UV, IR, NMR spectra, thin-layer chromatography...) are carried out for characterization of the biologically active substance or substances extracted from plants of the family of the Dictyotales.
The UV spectrum of the final active fraction, recorded in methanol, is characterized by several absorption bands situated at 202 nm, with a shoulder at 228 nm, between 260 and 270 nm, between 400 and 460 nm and at 630 nm.
At the end of these purification stages, thin-layer chromatography (TLC) with chemical development is also carried out (the developing reagents used are sulphuric-acid anisaidehyde, sulphuric-acid vanillin, phosphomolybdate and ethanolic sulphuric acid). After development, the presence of several spots is noted. The frontal retention times are: Rf = 0.15 and 0.90, 0.95, and correspond to the biologically active zones originating from preparative TLC carried out under the same conditions, that is to say a TLC plate with diol-grafted silica, elution with hexane/isopropanol 85/15.
AP/P/ 9 7 / 0 1 0 8 5
AP . Ο Ο 7 3 2
The mass spectra, the IR spectra and the proton or [13C] NMR spectra have also completed the data as regard the structure of the new biologically-active substances extracted from plants of the family of the Dictyotales according to the invention.
In particular, analysis of the 13 carbon NMR spectrum demonstrates the presence of the side chain having 4 to 10 carbon atoms in a straight or branched line and containing one to two double bonds, which is carried by the polycyclic structure.
It has also been possible to obtain the biologically active substances extracted from «
plants of the family of the Dictyotales by maceration or lixiviation of 1 g of dried io vegetable material in 5 ml of pure ethanol for 12 hours.
Ethanol is a solvent which is well accepted by the cells and is completely miscible with the aqueous nutrient solutions in which the cells are immerged.
The following purification stages were then carried out.
High pressure chromatography is carried out over a normal silica column. 20 μΙ of the biologically active fraction are injected into a high pressure chromatograph and the fraction is then eluted with a heptane/ether mixture (90/10) at a flow rate of 2 ml/min. All the activity of the substances extracted from plants of the family of the Dictyotales is found in the fraction eluted between 6.9 min and 8.5 min.
It is possible to carry out high performance liquid chromatography (HPLC) in the same manner. The HPLC column is packed with a C-i8-grafted silica, the eluent is a methanol/water 80/20 mixture and the flow rate is 4 ml/min. All the activity of the extracted substances is then concentrated in the fraction eluted after a retention time of between 16 and 18 min.
The chromatogram obtained with light diffusion detection shows, at this retention time, a certain amount of substance which constitutes the active fraction of the plant provided that the chromatography has been carried out under reduced pressure, such that evaporation of the mobile phase with entrainment of the active fraction does not take place.
The new biologically active substances extracted from plants of the family of the Dictyotales are thus characterized during the purification stages, and if the extractions have been carried out with acetone,’ by the following analytical data : ........
AP/P/ 9 7 / 0 1 0 8 5
AP.00732
- retention times in semi-preparative high performance liquid chromatography over a diol-grafted silica support with an eluent of hexane/isopropanol 92/8 of between 20 and 25 min and 35 and 40 min, '
- a retention time in semi-preparative high performance liquid chromatography over a Ci8-grafted silica support with an eluent of acetonitrile/water 85/15 of between 15 and 17 min,
- retention times in semi-preparative high performance liquid chromatography over a
Cis-grafted silica support with an eluent of acetonitrile/water/acetic acid 85/15/0.05 «
of between 17 and 20 min and 30 and 40 min.
io
During the purification stages and if the extractions have been carried out with ethanol, the analytical data are:
- a retention time in high pressure chromatography over a normal silica column with an eluent of heptane/ether (90/10) of between 6.9 min and 8.5 min,
- a retention time in high performance liquid chromatography packed with a engrafted silica column with an eluent of methanol/water 80/20 of between 16 and 18 min.
f
The biologically active substances are also characterized after the purification stages, and if the extractions have been carried out with acetone, by the following analytical data:
- a UV spectrum in methanol having several absorption bands situated at 202 nm, with a shoulder at 228 nm, between 260 and 270 nm, between 400 and 460 nm, and at 630 nm,
- a thin-layer chromatography (TLC) having, after chemical development (sulphuricacid anisaldehyde, sulphuric-acid vanillin, phosphomolybdate, ethanolic sulphuric acid) frontal retention times of 0.15, 0.90 and 0.95.
The substances extracted with the organic solvents are often difficult to handle (evaporation, hydration, risk of deflagration...). It is thus desirable to fix them on a solid support or supports, such as an organic absorbent polymer, such as, for example,' ceHulose;“absorbent~ minerals or mineral compositions; or absorbents
AP/P/ 9 7 / 0 1 0 8 5
AP. Ο Ο 7 3 2 s
(colloidal silica....), products which are more inert, such as the paraffins, the polyethylene glycols (PEG), the propylene glycols, polyvinylpyrrolidone etc.... All the inert supports of low degree of oxygenation are suitable.
The characteristics of the fixed substances can vary greatly according to the conditions of extraction of the substances from plants of the family of the Dictyotales, the fixing material, the stabilization conditions and the material on which the extraction solvent is fixed. The consistency thus varies, and the colour can vary «
from pure green to maroon.
io The present invention also relates to the biologically active substances adsorbed on an inert mineral or organic material and then desolvated.
The biologically active substances according to the invention extracted from plants of the family of the Dictyotales show very interesting pharmacological properties, and as a result are employed in therapeutics, in cosmetics, in nutrition, in human and veterinary dietetics, in implantology and in bone or joint surgery.
These substances are intended for use in the form of pharmaceutical, cosmetic and/or nutritional compositions or implants.
The biologically active substances extracted from plants of the family of the Dictyotales are intended for modification of the synthesis of glycosylated elements of the extracellular matrix (ECM) of animal and human tissues. These substances stimulate the synthesis of glycosaminoglycans (GAG) such as hyaluronic acid, chondroitin, chondroitin-sulphuric acids,-dermatan-sulphuric acid, heparan-sulphuric acid, heparin and keratan-sulphuric acid, and the synthesis of proteoglycans, such as aggrecan, decorin, biglycan, versican, fibromodulin, fibroglycan, syndecan, betaglycan and glypican.
The biologically active substances according to the invention are thus used in order to prepare compositions intended for modification of the synthesis of glycosylated elements of the extracellular matrix (ECM) of animal and human tissues, and in particular for stimulation of the synthesis of glycosaminoglycans (GAG) and of proteoglycans of the-extracellular matrix (ECM) of animal and humantissuesr-- --AP/P/ 9 7 / 0 1 0 8 5
AP. Ο Ο 7 3 2
The substances of the present invention are used in particular in order to prepare cosmetic or dermatological compositions intended for improvement of glycosylated syntheses of glycosaminoglycans and of proteoglycans in the skin.
The substances of the present invention stimulate the protein syntheses and the glycoside syntheses of the cells of connective tissue or of the mesenchyme.
The substances are used in order to prepare topical compositions intended for indirect remodelling of the activity of connective or mesenchymal cells by direct action on the epithelial cells.
io The substances extracted from plants of the family of the Dictyotales stimulate the golgial and membrane syntheses of glycosaminoglycans of the ECM and the golgial syntheses of proteoglycans of the ECM.
These substances thus increase, for example, the synthesis of collagens, of chondroitin-sulphuric acid, of dermatan-sulphuric acid, of hyaluronic acid...
These substances are used in order to prepare compositions intended for stimulation of the golgial and membrane syntheses of glycosaminoglycans of the ECM and the golgial syntheses of proteoglycans of the ECM.
The substances of the present invention are active on the cells of the skin (fibroblasts, keratinocytes), on the cells of the bone (osteoblasts, chondrocytes) and on the cells of the non-osseous articular tissue (synoviocytes).
In humans, the ingestion of biologically active substances extracted from plants of the family of the Dictyotales, like the plant in the dried state itself, causes an increase in the synthesis of glycosylated elements of the ECM of the mesenchymal tissues, and more particularly of the skin (dermis and epidermis) and of the bone (cartilage, spongy bone, trabecular bone, connecting cartilage...).
The substance extracted from plants of the family of the Dictyotales are thus used in particular in order to prepare pharmaceutical compositions intended for prevention and/or treatment of tissue lesions of the skin, of the bone and of the cartilage.
Generally, these substances are used in order to prepare compositions intended for prevention and/or treatment of conditions involving glycosylated elements of the extracellular matrix of animal and human tissues.
AP/P/ 9 7 / 0 1 0 8 5
AP. Ο Ο 7 3 2
The Applicant has demonstrated in his studies that this activity differs from that induced by the majority of activating substances, such as oestradiol and vitamin D3 (1-25-(OH)2D3), vitamin C etc... The active substance or substances-contained in the plants express their activity even in the presence of deleterious agents, such as the interleukins (for example IL-1), and these biologically active substances thus have a repairing activity.
These biologically active substances also have an indirect activity on the cells by acting by the intermediary of messengers, such as a cytokine, a growth factor or a hormone, secreted by the first cell population reached by the active substances io extracted from plants and intended for the target cells.
The activity of the substances extracted from plants of the family of the Dictyotales is expressed on cells originating from animal species belonging to such diverse branches as the Annelidae, the Ascidiae, the Arthropoda, the molluscs, the bivalves (Conchifera), the Echinodermata, the birds and the mammals.
The biologically active substances extracted from plants of the family of the
Dictyotales are also used in order to prepare nutritional compositions intended for improving the rearing of Arthropoda and Conchifera, as well as the quality of the * shells of eggs.
The substances extracted from plants of the family of the Dictyotales are also of great advantage in bone surgery. In fact, these substances preserve the phenotype of human osteoblasts during grafting and can be inserted with a biomaterial implanted in the vicinity of a joint to regenerate the bone and the articular surfaces. The substances are thus also used in order to prepare compositions intended for prevention and/or treatment of joint conditions.
The substances of the present invention are also used in order to prepare compositions for local use intended for prevention and/or treatment of loco-regional conditions involving glycosylated elements of the extracellular matrix.
30
The biologically active substances are also used in order to prepare compositions intended for prevention and/or treatment of conditions associated with a
AP/P/ 9 7 / 0 1 0 8 5
AP. Ο Ο 7 3 2 degeneration of the extracellular matrix, and also for regeneration of the cartilaginous tissue, or for addition to foods.
The present invention also relates to pharmaceutical, cosmetic and/or nutritional compositions which modify the synthesis of glycosylated elements of the extracellular matrix of animal and human tissues, characterized in that they comprise, as the active principle, one or more biologically active substances extracted from plants of the family of the Dictyotales, in combination or as a mixture with an inert, non-toxic excipient or vehicle suitable for the envisaged use, and if io appropriate one or more active principles having a complementary action.
The pharmaceutical, cosmetic and/or nutritional compositions according to the invention are intended for digestive, parenteral, percutaneous, topical or rectal administration. The compositions are thus in the form of non-coated or coated tablets, sugar-coated tablets, capsules, soft gelatine capsules, pills, tablets, sachets, syrups, powders for ingestion or external use, adjuvant compositions for postoperative cicatrization, for burns or traumatisms; suppositories; injectable aqueous solutions or suspensions packaged in ampoules; creams, gels or pomades; or solutions for percutaneous use in a penetrating polar solvent.
The compositions for cutaneous administration but having systemic effects are particularly novel, since it has been demonstrated that under these conditions the biologically active substances extracted from plants of the family of the Dictyotales, when applied to keratinocytes (cutaneous epidermis), were capable for stimulating secretion of a factor by acting on the chondrocytes, the synoviocytes, the osteoblasts and, without doubt, on other mesenchymal cells.
The present invention also relates to implants, characterized in that they comprise, as the active principle, one or more biologically active substances extracted from plants of the family of the Dictyotales, in combination or as a mixture with an inert, non-toxic excipient or vehicle suitable for the envisaged use, and if appropriate one or more active principles having a complementary action.
AP/P/ 9 7 / 0 1 0 8 5
AP . 0 0 7 3 2
The following examples and results illustrate the invention. They do not limit it in any way.
EXAMPLE 1 :
Activity study of substances extracted from plants of the Dictyotaies family
1) Activity study io
An activity study has been achieved on all fractions susceptible to be isolated during a high performance liquid chromatography or a high pression chromatography in order to show that the observed effects are indeed attribuable to biologically active substances specific of plants.
The applicant used two halfquantitative evaluation methods in order to study the activity of these plants.
From a tissular or a cellular culture, constituent of the extracellular matrix selected either by immunomarking of cells fixed thanks to its specific antibody ; or after cells 20 destruction is detected, a chromatography on gel or an electrophoresis (chromatography under an electric field) with revelation and identification of the substance by specific antobody is achieved.
In both cases, the specific antibody is revelated by a second antibody which is coupled either to a fluorescent molecule, or to an enzyme of which activity underscore a chromophore brought by a substrate.
The relative quantifying can be achieved by picture analysis (immunofluorescence) or by simple spectrophotometry when a coloured substrate is used (Western Blot).
When picture analysis is necessary a BIOCOM 200 analyser is used which quantify results from several negatives which have been obtained on several cellular cultures. In every case, values are expressed in relative value (half-quantitative evaluation) in relation to a· control and/or in relation to the total quality-ofrthe-—......
AP/P/ 9 7 / 0 1 0 8 5
AP . ο ο 7 3 2 synthetized proteins. The half-quantitative evaluation enable results to be compared between each other. Nevertheless, it is not possible to compare the synthesis of a component to another therefore because of the affinity of antibodies which, although specifics they are, is not the same for two antigen-antibody couples. Results are comparable between each other for a same antibody.
Matricial synthesis of isolated cells have been studied from tissues fragments taken off during surgery operations. Cultures have been achieved in monolayer primary culture and results have been confirmed by three-dimensional cellular cultures.
io Cultures of tissular fragments, skin, joints, bones provide the same results.
2) Results
Results are expressed by a number corresponding to the detected signal value.
In the following tables, « BAS » letters indicate biologically active substances extracted from plants of the dictyotales family.
• Dermatan sulfuric acid synthetized by human fibroblasts in a monolayer primary 20 culture:
AP/P/ 9 7 / 0 1 0 8 5
| Average | Standard deviation | |
| Fibroblasts in a control medium | 32 | 0,54 |
| Fibroblasts with a medium with BAS added | 625 | 21,87 |
• Hyaluronic acid synthetized by human fibroblasts in a monolayer primary culture :
| Average | Standard deviation | |
| Fibroblasts in a control medium | 75 | 0,67 |
| Fibroblasts with a medium with BAS added | 428 | 52,10 |
AP. Ο Ο 7 3 2 • Chondro'itin sulfuric acid synthetized by human chondrocytes in a monolayer primary culture ;
| Average | Standard deviation | |
| Control chondrocytes | 56 | 0,85 |
| Chondrocytes with BAS | 445 | 19,45 |
· Hyaluronic acid synthetized by human chondrocytes in a monolayer primary culture :
| Average | Standard deviation | |
| Control chondrocytes | 58 | 17 |
| Chondrocytes with BAS | 108 | 21 |
10 3) Activity control
This control have been achieved in accordance with litterature indications CL concerning three-dimensional culture. G.
There, an alginic acid gel has been used.
• Chondro'itin sulfuric acid synthetized by human chondrocytes in a threedimensional culture ;
| Average | Standard deviation | |
| Control chondrocytes | 37 | 7 |
| Chondrocytes with BAS | 94 ' | 8 |
• Hyaluronic acid synthetized by human chondrocytes in a three-dimensional culture :
AP. u Ο 7 ό Ζ
| Average | Standard deviation | |
| Control chondrocytes | 48 | 36 |
| Chondrocytes with BAS | 151 | 50 |
Quite similar results have been obtained with osteoblasts cultures collected from bone samples on diverse varieties of mammalians.
Furthermore, in order to confirm this result, biologically active substances extracted from plants of the Dictyotales family have been applied to tissular cultures of normal or damaged cartilages. It has been noted that a damaged cartilage was poor in synthesis, and in its reserves in glycosaminoglycans of the sulfate chondro'itin and hyaluronic acid types. A damaged cartilage treated by biologically active io substances, extracted from plants of the Dictyotales family, has shown greater synthesis rates than the healthy control, untreated by active substances.
4) Pharmacological action of the biologically active substances «
Pharmacological action of the biologically active substances extracted from plants of Dictyotales family is objectived by :
a) Healing activities of the substances in the presence of a deleterious inhibitory agent of the extracellular matrix.
b) Indirect action of substances via a messenger such as a cytokin, a growth factor or an hormone.
Nowadays, litterature agrees to describe most of arthrosic phenomenons as a result of degeneration of the articular areas.
AP/P/ 9 7 / 0 1 0 8 5
a) Healing activities
AP . υ Ο 7 3 2
The therapeutic activity of a substance is envisaged through the possibility of responding to the deleterious action of a biological intervener responsible for the pathological process. Interleukin 1 (IL-1) is the largest physiological intervener.
That’s the reason why, the activity of biologically active substances extracted from plants of the Dictyotales family have been evaluated on the production of glycosaminogiycans elaborated by mesenchymateous cells cultivated in the presence of IL-1.
.0 • Cultures results in the presence of IL-1 • Hyaluronic acid synthetized by human fibroblasts in a monolayer culture :
| Average | Standard deviation | |
| Fibroblasts cultivated in the presence of IL-1 | 36 | 9 |
| Fibroblasts cultivated in the presence of IL-1 and BAS | 451 | 50 |
AP/P/ 9 7 / 0 1 0 8 5 • Dermatan sulfuric acid on chondroitin sulfuric acid synthetized by human fibroblasts in a monolayer culture :
| Average | Standard deviation | |
| Fibroblasts cultivated in the presence of IL-1 | 14 | 9 |
| Fibroblasts cultivated in the presence of IL-1 and BAS | 632 | 17 |
Hyaluronic acid synthetized by human osteoblasts in a monolayer culture :
AP . 0 0 7 3 2
| Average | Standard deviation | |
| Fibroblasts cultivated in the presence of IL-1 | 38 | 1 |
| Fibroblasts cultivated in the presence of IL-1 and BAS | 232 | 5 |
• Chondroitin hyaluronic acid synthetized by human osteoblasts in a monolayer culture :
| Average | Standard deviation | |
| Fibroblasts cultivated in the presence of IL-1 | 28 | 5 |
| Fibroblasts cultivated in the presence of IL-1 and BAS | 280 | 12 |
• Hyaluronic acid synthetized by human chondrocytes in a three-dimensional culture :
AP/P/ 9 7 / 0 1 0 8 5
| Average | Standard deviation | |
| Fibroblasts cultivated in the presence of IL-1 | 78 | 16 |
| Fibroblasts cultivated in the presence of IL-1 and BAS | 125 | 17 |
io · Chondroitin sulfuric acid synthetized by human chondrocytes in a threedimensional culture :
| Average | Standard deviation | |
| Fibroblasts cultivated in the presence of IL-1 | 25 | 3 |
| Fibroblasts cultivated in the presence of IL-1 and BAS | 470 | 21 |
AP. 0 Ο 7 3 2
IS
The same kind of results have been obtained with cellular types as well in explants cultures. Half-quantitative evaluation with explants is difficult because section plans must be taken in account.
1) Indirect action :
The applicant noted that, surprisingly, incubated cells with the biologically active substances (BAS) extracted from plants of the Dictyotales family were susceptible to transmitt the signal to other cells, which signal was detected by the latter at the io contact with biologically active substances. These biologically active substances thus can stimulate the secretion of a second messenger. This messenger reaches other cellular types and stimulate proteoglycans synthesis. i c
c
In order to underscore this phenomenon, tests have been realized in the following 15 manner. c f*
To a keratinocyte culture (human epidermis cells), the biologically active substances have been added in the culture medium. After several hours of incubation, cells are rinsed several times in order to eliminate the rest of biologically active substances 20 (BAS). Then, a new medium (KEM or Mac Coy for example) without foetal calf or animal serum is added. After a new incubation, this medium is reuptaken. The conditionned medium thus obtained is lyophilized. The lyophilizate is reuptaken then diluted at % or 1/10 by the specific medium wherein it operate the second culture (DMEM for fibroblasts, Mac Coy for osteoblasts for example). Cells cultures treated 25 by the conditionned medium issued from keratinocytes, increase proteoglycans synthesis in the same proportions that if they had been treated themselves directly by biological active substances while those incubated in the presence of a conditionned medium by keratinocytes, but not incubated by biologically active substances, pratically don’t have modified their synthesis.
Furthermore, response to the conditionned medium varies depending on whether the lyophilizate reuptaking before dilution is made with alcohol or with an aqueous medium. .........
AP.'O/
AP . 0 0 7 3 2
In some experimental conditions, osteoblasts show a best response when the medium conditionned by keratinocytes is reuptaken by alcohol, while the same treatment, between fibroblasts on one hand and osteoblasts on the other hand, produces a better response if the lyophilizate is reuptaken directly by medium. It leads to suppose that messengers secreted by cells and producing a same signal for a same population, are different. This test allows the applicant to envisage' the possibility for modifying the synthesis of proteoglycans from tissues deeper than skin, by application of a composition, which contains active components, on skin «
keratocytes or on epthelial tissues, io
Example II :
Compositions
1) As an exemple, one of the following extracts (which contain the biologically active substances) can be prepared.
| Dryed plant | 200 g |
| Cyclohexane | 1 000 g |
AP/F/ 9 7 / 0 1 0 8 5 or:
| Dryed plant | 200 g |
| Ethanol | 1 000 g |
Fixation of the extract which contain biologically active substances (BAS) on a support:
| Organic solution | 200 g |
| Hydroxypropylmethylcellulose | 1 000 g |
The organic solution is evaporated on the cellulose derivative support
AP . 0 0 7 3 2 or:
| Organic solution | 20 g |
| Polyethyleneglycol (P.E.G.) 4 000 or 6 000 | 1 000 g |
the organic solution is distillated in liquid or solid PEG. Organic solution support ratios vary greatly and are linked to the wanted effect (mass effect, delayed formulation, in situ action, general systemic action’ etc.)
2) General use composition :
io Capsules and tablets formulations, wherein active substances are extracted with ethanol and fixed on an inert support, turns out to be simplest one. In order to do it, biologically active substances extracted with ethanol are mixed with microcrystalline cellulose, with a lubricating agent such as talc, and with a compressive adjuvant such as glycerol behenate.
Capsules are achieved by using the absorbate of biologically active substances extracted with ethanol, fixed on polyethyleneglycol 4 000 or 6 000 and diluted with colloidal silica of the Aerosil(R) or Sippernat(R) type.
Transcutaneous way is classically formulated, with or without a tank, and with classical excipients of the Transcutol(R) type.
Injectable way is conceivable with purified biologically active substances which are made dissolved in a suitable liquid for injection in a solution or in a suspension.
25 Formulation examples :
a) Capsules based on biologically active substances (BAS) extracted from plants of the Dictyotales family s 8 0 10 / L 6 /d/dV
AP . 0 0 7 3 2
| BAS fixed on polyethyleneglycol 6 000 | 95 % |
| Silica | 5 % |
Capsules filling is made as usual.
b) Tablets based on biologically active substances (BAS) extracted from plants of 5 the Dictyotales family :
| BAS fixed on cellulose | 25 % |
| Cellulose | 65 % |
| Talc | 1,5 % |
| Glycerol behenate | 8,5 % |
Preferred compositions for pharmaceutical use are forms which can be administered orally such as tablets, dragees, capsules, which contain as active ingredient at least io one biologically active substance extracted from plants of the Dictyotales family or adsorbate of biologically active substances on an inert support, in conjunction or admixed with inert, not toxic, suitable for pharmaceutical use diluent or carrier, and eventually one or several active ingredients having a complementary action.
For alimentary use, biologically active substances extracted from plants of the Dictyotales family will be diluted in a nutritive alimentary support such as a meal, or inert such as cellulose or a cellulose rich preparation.
These compositions concern notably shellfishes breeding, and for example shrimps.
AP/P/ 9 7 / 0 1 0 8 5
Example shrimps
AP . 0 0 7 3 2
| BAS | 12,1 |
| Dulectin | 23,9 |
| Calcium carbonate | 5,0 |
| Asperella | 1,0 |
| Wheat germ powder | 54,05 |
| Sippernat | 3,95 |
This formulation, administered at a dose of 1,5 kg during a month to a basin of 180 000 shrimps, has permitted an improvement of hatching survival and an increase of the animal weight, at maturity of 10 % ± 2 %.
So, biologically active substances can improve animals medium weight and/or grow shorter the time of maturation.
A similar experiment on laying hens showed that the number of broken eggs during io the second cycle of laying was reduced of 2 %.
3) Loco-regional use compositions :
Implants use (pellets : small tablets placed under skin) is already classical. It founds 15 large applications in substitutive hormonal treatment. It allows a prolonged treatment. Putting in by the surgical way biomaterials such as synthetic polymers (polylactic acid, polyacrylic acid), minerals : hydroxyapatite, calcium phosphate, biomaterials : mother-of-pearl, coral... impregnated of active ingredients consisting in the biologically active substances extracted from plants of the Dictyotales family is envisaged and doubtless leads to interesting results on the stimulation of proteoglycan systhesis of the extracellular matrix.
4) Topical compositions destined for application with a general, dermatologic or cosmetic aim :
AP/P/ 9 7 / 0 1 0 8 5
AP. Ο ο 7 3 2
For the cosmetical or dermatological use, creams or gels will be preferably used, of which use in the field is the most convenient and effective. Without being restrictive, these formulations use emulsions of the oil in water or water in oil type. These emulsions are designated as lotions, day or night creams, in some applications of the cosmetological field and in dermatological applications, ointments, gels, gelcream mixed formulations.
As an example, an emulsion formulation can be cited ; these formulations contain all at least three constituants : water, fatty bodies, emulsifying or tensio-active agents, io Obviously, other substances such as colouring agents, texture agents, active ingredients associated or not, preservatives, stabilizing agents of pH, of oxidation, can intervene in the final formula. Ointments are formulations which group together only lipophilic agents. Gels are compositions having a diaphaneous appearance wherein water and sometimes lipophilic components (or silicone) are in a colloid or a colloidal suspension state.
Concentrations in biologically active substances (BAS) can vary in great proportions, which range between 0,01 and 20 % of the emulsion mass, where 0,01 % is the threshold dose. It can also be envisaged the use of encapsulated forms of biologically active substances (liposomes, nanospheres, nanocapsules...) because these are susceptible to improve activity. With 20 % of active ingredient, it is necessary to noticeably modify the formulation, the activity being probably at a plateau level.
Modern forms of formulation resorted to gels. Lots of them are formulated with the aid of polymers derivated from acrylic acid described under the name of carbomers. Other types of molecules can lead to gels such as cellulose and its derivatives, colloidal silicas, uronic acid polymers, mannans, galactomannans, xanthan gums, etc...
Example : Oil in water cream which contain active substances extracted with ethanol dryed beforehand.
AP/P/ 9 7/01085
AP . ο Ο 7 3 2
| Tefose 2 000 © | 11 |
| Lanoline wax | 3,5 |
| Geleol © | 3,5 |
| Water | 76,7 |
| Preservative | qs |
| BAS (soluble in water) | 5,0 |
| Flavour | 0,3 |
| BAS under vesicular form (liposomes...) | 0,5 |
| Carbomer | 0,5 |
| Solution of NaOH (10 %) | QSpH 6,5 |
| Water | QSP 100 ml |
| Preservative, colouring agent |
It is obviously possible to contemplate other formulations in topical, pharmaceutical and cosmetical applications, such as sponges, patches with local effects, powders, sticks (lipstick)...
Claims (14)
- WHAT IS CLAIMED IS1. Biologically-active substances which modify the synthesis of glycosylated elements of the extracellular matrix of animal and human tissues from the plants5 of the family of the Dictyotales.
- 2. Biologically-active substances according to claim 1, characterized in that they have a polycyclic structure bearing a side chain having from 4 to 10 carbon atoms in straight or branched chain, and possessing one or two double bonds.io
- 3. Biologically-active substances according to one of the claims 1 or 2, characterized in that they show the following analytical data :- retention times by semi-preparative high performance liquid chromatography on a diol grafted silica support and with an eluent made of hexane / isopropanol in15 the ratio 92:8, ranging from 20 to 25 min and from 35 to 40 min- a retention time by semi-preparative high performance liquid chromatography on a Cis grafted silica support and with an eluent made of acetonitrile / water in the <ratio 85:15, ranging from 15 to 17 min- retention times by semi-preparative high performance liquid chromatography on 20 the Cis grafted silica support and with an eluent made of acetonitrile / water / acetic acid in the ratio 85:15:0,05, ranging from 17 to 20 min and 30 to 40 min- a retention time by high pressure chromatography on a column filled with normal silica and with an eluent heptane / ether (90:10) ranging from 6,9 min to 8,5 min- a retention time by high performance liquid chromatography fitted with Ci8 25 grafted silica column using an eluent made of methanol / water 80/20, ranging from 16 to 18 min
- 4. Biologically-active substances according to · one of the claims 1 to 3, characterized by an UV spectrum in methanol showing several absorption bands30 located at 202 nm with a shoulder at 228 nm, between 260 and 270 nm, between 400 and 460 nm and at 630 nmAP/P/ 9 7 / 0 1 0 8 5AP . 0 0 7 3 2 by a TLC showing after chemical revelation (anisaldehyde-sulphuric acid, vanillinsulphuric acid, phophomolybdate, sulfuric acid / ethanol), frontal retention times of .15, .90 and .95 .
- 5 5. Bioiogically-active substances according to one of the claims 1 to 4, characterized in that they are adsorbed on an inert, mineral or organic material then dessoivated.
- 6. A process for producing bioiogically-active substances according to one of the io claims 1 to 4, characterized in that the plant of the Dictyotale family is submitted to a drying, and/or to a lyophylisation then to a grinding followed with one or several extractions of the vegetable matter with an organic solvent selected from the group consisting of lower alkanols, aliphatic ketones, alkanes, cycloalkanes, halogenated solvents, aromatic solvents, esters, ethers and the like, to obtain an15 organic extract of the plant, the organic extract is dried, through evaporation of the solvent, the dry organic extract is purified by means of one or several steps of purification successively performed by liquid/Iiquid confronting, by low pressure or high pressure chromatography on column, by liquid high performance chromatography, to produce the active substances of the Dictyotales family.
- 7. A process for producing the bioiogically-active substances according to claim 6, characterized in that preferably ethanol or acetone is used as an organic solvent.
- 8. A process for producing the bioiogically-active substances according to claims 625 and 7, characterized in that the used ratios between the vegetable matter (plant) and the organic solvent preferably are of 1 g vegetable matter for 5 ml solvent and the contracting times between the vegetable matter and the organic solvent range from 12 hours to 5 days.30
- 9. Pharmaceutical, cosmetic, and/or alimentary compositions to modify the synthesis of glycosylated elements of the extracellular matrix of the animal or human tissues, characterized in that they contain as the active ingredient one or several bioiogically-active substances according to one of the claims 1 to 5, admixed or inAP/P/ 9 7 / 0 1 0 8 5AP . Ο Ο 7 3 2 conjunction with an inert non toxic, suitable for the intended use, carrier or vehicle together optionally with one or several active ingredients having a complementary action.5
- 10.Compositions according to claim 9, wherein the inert carrier or vehicle is one among those suitable for the administration per digestive, parenteral, percutaneous, topical or rectal ways.
- 11. Use of the biologically-active substances according to one of claims 1 to 5 in io view of the performance of compositions intended to modify the synthesis of glycosylated elements of the extracellular matrix of the animal and human tissues.
- 12. Use of the biologically-active substances according to one of claims 1 to 5, in view of the performance of compositions intended to stimulate the synthesis of15 glycosaminoglycans and proteoglycans of the extracellular matrix of the animal and human tissues.
- 13. Use of the biologically-active substances according to one of claims 1 to 5, in view of the performance of compositions intended to stimulate the golgian and20 membranar synthesis of the glycosaminoglycans of the extracellular matrix and the golgian synthesis of the proteoglycans of the extracellular matrix.
- 14. Use of the biologically-active substances according to one of the claims 1 to 5, in view of the performance of compositions intended to prevent and/or treat the25 ailments involving the glycosylated elements of the extracellular matrix of the animal and human tissues.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9600522A FR2743723B1 (en) | 1996-01-18 | 1996-01-18 | USE OF EXTRACT FROM PLANTS OF THE DICTYOTAL FAMILY FOR THE PREPARATION OF PREPARATIONS FOR REFORMING THE GLYCOSYL ELEMENTS OF THE EXTRACELLULAR MATRIX OF LIVING TISSUES |
| PCT/FR1997/000106 WO1997025998A1 (en) | 1996-01-18 | 1997-01-20 | Substances extracted from dictyotales, preparation method therefor, and compositions containing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9701085A0 AP9701085A0 (en) | 1997-10-31 |
| AP732A true AP732A (en) | 1999-02-10 |
Family
ID=9488210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1997/001085A AP732A (en) | 1996-01-18 | 1997-01-20 | Substances extracted from dictyotales, preparation method therefor, and compositions containing same. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5961981A (en) |
| EP (1) | EP0817641B1 (en) |
| JP (1) | JPH11502235A (en) |
| KR (1) | KR19980703075A (en) |
| CN (1) | CN100536858C (en) |
| AP (1) | AP732A (en) |
| AT (1) | ATE241996T1 (en) |
| AU (1) | AU724083B2 (en) |
| BR (1) | BR9704626A (en) |
| CA (1) | CA2216600A1 (en) |
| DE (1) | DE69722514T2 (en) |
| DK (1) | DK0817641T3 (en) |
| ES (1) | ES2219748T3 (en) |
| FR (1) | FR2743723B1 (en) |
| HU (1) | HUP9900952A3 (en) |
| NZ (1) | NZ326391A (en) |
| OA (1) | OA10508A (en) |
| PL (1) | PL322310A1 (en) |
| RU (1) | RU2195955C2 (en) |
| WO (1) | WO1997025998A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2760192B1 (en) * | 1997-03-03 | 1999-05-21 | Inovat Sarl | PROCESS FOR OBTAINING NEW BIOLOGICALLY ACTIVE SUBSTANCES, THE SUBSTANCES THUS OBTAINED AND THE COMPOSITIONS THEREOF |
| GB9709082D0 (en) | 1997-05-06 | 1997-06-25 | Ciba Geigy Ag | Organic compositions |
| FR2803523B1 (en) * | 2000-01-10 | 2006-09-01 | Texinfine Sa | NOVEL COMPOSITIONS BASED ON DICTYOTAL EXTRACTS AND THEIR USE |
| FR2811563B1 (en) * | 2000-07-13 | 2003-06-20 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, COMPRISING DHEA AND / OR A PRECURSOR OR DERIVATIVE, AND AT LEAST ONE COMPOUND INCREASING THE SYNTHESIS OF GLYCOSAMINOGLYCANS |
| KR100386416B1 (en) * | 2000-08-31 | 2003-06-02 | 주식회사 내비켐 | Antifouling activity of marine algal metabolite |
| KR100419134B1 (en) * | 2000-10-16 | 2004-02-14 | 엔프라니 주식회사 | Cosmetic material containing Padina Pavonica extract |
| FR2827303B1 (en) * | 2001-07-13 | 2004-09-10 | Texinfine Sa | PROCESS FOR OBTAINING A TITLE PREPARATION OF ALGAE AND THE TITLE PREPARATIONS THEREFROM |
| US7354956B2 (en) * | 2002-04-12 | 2008-04-08 | L'oreal | Composition containing a sapogenin and use thereof |
| CA2508309A1 (en) * | 2002-12-05 | 2004-06-17 | Takara Bio Inc. | Remedy |
| WO2007032962A2 (en) * | 2005-09-09 | 2007-03-22 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
| FR2896692A1 (en) * | 2006-01-30 | 2007-08-03 | Jean Alexis Grimaud | NEW COSMETOLOGICAL AND DERMATOLOGICAL COMPOSITIONS BASED ON ALGAE EXTRACTS |
| GB0921001D0 (en) | 2009-11-30 | 2010-01-13 | Aqua Bio Technology Asa | Products and uses |
| FR3106057B1 (en) | 2020-01-10 | 2022-02-04 | Gelyma | Cosmetic composition comprising extracts of Padina Pavonica to improve healing of the skin |
| FR3106061B1 (en) | 2020-01-10 | 2022-10-21 | Gelyma | Cosmetic composition comprising extracts of Padina Pavonica to improve the formation and maturation of the stratum corneum |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0655250A1 (en) * | 1993-11-22 | 1995-05-31 | Texinfine | Compositions of Padina algae or their extracts, and their pharmaceutical, food compositions, or use for the culture of molluscs or arthropodes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1249447B (en) * | 1991-08-28 | 1995-02-23 | Arrigo Claudio D | VEGETABLE EXTRACTION ANTINEOPLASTIC DRUG. PROCEDURE FOR ITS PREPARATION. |
-
1996
- 1996-01-18 FR FR9600522A patent/FR2743723B1/en not_active Expired - Fee Related
-
1997
- 1997-01-20 DK DK97901124T patent/DK0817641T3/en active
- 1997-01-20 WO PCT/FR1997/000106 patent/WO1997025998A1/en active IP Right Grant
- 1997-01-20 PL PL97322310A patent/PL322310A1/en unknown
- 1997-01-20 ES ES97901124T patent/ES2219748T3/en not_active Expired - Lifetime
- 1997-01-20 DE DE69722514T patent/DE69722514T2/en not_active Expired - Fee Related
- 1997-01-20 RU RU97117177/14A patent/RU2195955C2/en active
- 1997-01-20 AT AT97901124T patent/ATE241996T1/en not_active IP Right Cessation
- 1997-01-20 BR BR9704626-4A patent/BR9704626A/en not_active Application Discontinuation
- 1997-01-20 JP JP9525757A patent/JPH11502235A/en not_active Ceased
- 1997-01-20 US US08/930,365 patent/US5961981A/en not_active Expired - Fee Related
- 1997-01-20 CA CA002216600A patent/CA2216600A1/en not_active Abandoned
- 1997-01-20 NZ NZ326391A patent/NZ326391A/en unknown
- 1997-01-20 EP EP97901124A patent/EP0817641B1/en not_active Expired - Lifetime
- 1997-01-20 CN CNB971902186A patent/CN100536858C/en not_active Expired - Fee Related
- 1997-01-20 KR KR1019970706484A patent/KR19980703075A/en active IP Right Grant
- 1997-01-20 AP APAP/P/1997/001085A patent/AP732A/en active
- 1997-01-20 HU HU9900952A patent/HUP9900952A3/en unknown
- 1997-01-20 AU AU14480/97A patent/AU724083B2/en not_active Ceased
- 1997-09-18 OA OA70079A patent/OA10508A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0655250A1 (en) * | 1993-11-22 | 1995-05-31 | Texinfine | Compositions of Padina algae or their extracts, and their pharmaceutical, food compositions, or use for the culture of molluscs or arthropodes |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69722514D1 (en) | 2003-07-10 |
| CA2216600A1 (en) | 1997-07-24 |
| HUP9900952A2 (en) | 1999-07-28 |
| US5961981A (en) | 1999-10-05 |
| KR19980703075A (en) | 1998-09-05 |
| AU724083B2 (en) | 2000-09-14 |
| WO1997025998A1 (en) | 1997-07-24 |
| JPH11502235A (en) | 1999-02-23 |
| DK0817641T3 (en) | 2003-09-29 |
| DE69722514T2 (en) | 2004-04-29 |
| AU1448097A (en) | 1997-08-11 |
| AP9701085A0 (en) | 1997-10-31 |
| FR2743723B1 (en) | 1998-04-17 |
| BR9704626A (en) | 1999-12-28 |
| HUP9900952A3 (en) | 2000-11-28 |
| RU2195955C2 (en) | 2003-01-10 |
| NZ326391A (en) | 2001-06-29 |
| EP0817641A1 (en) | 1998-01-14 |
| CN1183045A (en) | 1998-05-27 |
| CN100536858C (en) | 2009-09-09 |
| ATE241996T1 (en) | 2003-06-15 |
| EP0817641B1 (en) | 2003-06-04 |
| OA10508A (en) | 2002-04-24 |
| FR2743723A1 (en) | 1997-07-25 |
| PL322310A1 (en) | 1998-01-19 |
| ES2219748T3 (en) | 2004-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP732A (en) | Substances extracted from dictyotales, preparation method therefor, and compositions containing same. | |
| DE60030766T2 (en) | USE OF AN EXTRACT OF THE GENUS VACCINIUM AS ANTI-GLYCATION AGENCY | |
| JP5047433B2 (en) | Process for producing a composition by extraction of the nacre, comprising all the components of the nacre, the composition obtained using this process, and the use of this composition in cosmetics and dermatology | |
| KR101219520B1 (en) | Anti-inflammatory, anti-oxidative or anti-bacterial compositions | |
| CN1899257A (en) | Plant based formulations for improving skin moisture, texture, and appearance | |
| DE69819006T2 (en) | USE OF GINSENOSIDE RB1 FOR STIMULATING ELASTINE SYNTHESIS | |
| CN101815498B (en) | Use of lignan compound for anti-wrinkle treatment | |
| EA013502B1 (en) | Composition based on vegetal extracts of ajuga reptans for preventing or treating of androgenic alopecia, telogenic defluvium and acne | |
| KR102298530B1 (en) | Cosmetic composition comprising centella asiatica extracts cultivated by aquaponics | |
| KR20160091300A (en) | Use of a brassocattleya marcella koss orchid extract as an active agent to prevent or delay the appearance of signs of cutaneous aging | |
| KR20110076797A (en) | Extract of the plant ravenala madagascariensis and use as cosmetic hydrating agent | |
| US20070116789A1 (en) | Extracts of durian fruit for use in skin care compositions | |
| KR20180001652A (en) | Cosmetic composition for skin barrier comprising extract of Buddleia officinalis or fractions thereof | |
| CN1870971A (en) | Cosmetic composition comprising extract from mallotus japonicus for improving skin wrinkle | |
| KR102523606B1 (en) | Cosmetic composition containing polysaccharide extracted from alfalfa seeds | |
| KR101074132B1 (en) | Cosmetic composition containing Salicornia herbacea callus extracts and Pelvetia Canaliculata extracts for improving skin wrinkle or enhancing elasticity | |
| KR101618726B1 (en) | Method for making protein from Pollock skin | |
| KR20020084619A (en) | Cosmetic composition containing phellinus linteus extract and vitis vinifera l. fermented solution and having anti-wrinkle effect | |
| JP2021187787A (en) | Exosome secretagogue, exosome uptake promoter, exosome secretion-promoting beauty composition, and exosome secretion promoting method | |
| KR101609217B1 (en) | Method for making glycoprotein from jelly fish and cosmetics containing the same | |
| CN114262360B (en) | Hairtail antioxidant peptide and antioxidant facial cream thereof | |
| KR20200004230A (en) | Cosmetic Composition Containing Vitamin C Stabilized by Moringa Seed Bark | |
| KR102682941B1 (en) | Method for producing PDRN from Rose plant cells | |
| JPH06128141A (en) | External agent for skin | |
| KR102298531B1 (en) | Cosmetic composition comprising saururus chinensis extracts cultivated by aquaponics |